Twenty-nine patients with metastatic breast cancer were treated orally with idarubicin (15 mg/m2 X 3 days every 3-4 weeks). Objective response was seen in 31\% of all patients. Toxicity was acceptable. There should be further clinical trials of new anthracycline antibiotic.
Idarubicin in advanced breast cancer: a phase II study / R., Lionetto; P., Pronzato; Conte, Pierfranco; M. R., Sertoli; D., Amoroso; R., Rosso. - In: CANCER TREATMENT REPORTS. - ISSN 0361-5960. - STAMPA. - 70:(1986), pp. 1439-1440.
Idarubicin in advanced breast cancer: a phase II study.
CONTE, Pierfranco;
1986
Abstract
Twenty-nine patients with metastatic breast cancer were treated orally with idarubicin (15 mg/m2 X 3 days every 3-4 weeks). Objective response was seen in 31\% of all patients. Toxicity was acceptable. There should be further clinical trials of new anthracycline antibiotic.
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
